Pyrimidine-2,4,6-triones for ALS Protein Aggregation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases focused on glutamate-mediated excitotoxicity are inadequate, as evidenced by the limited efficacy of existing drugs like riluzole, which only extends median survival by 2-3 months, indicating a need for new compounds that address abnormal protein aggregation.
Innovation Solution
Development of pyrimidine-2,4,6-trione (PYT) compounds that inhibit or reverse abnormal protein aggregation, such as SOD1 protein aggregates, and modulate proteasome activity to treat ALS and other neurodegenerative diseases.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current ALS treatments focusing on glutamate-mediated excitotoxicity are used, then some therapeutic effect is achieved, but the treatment efficacy is insufficient with only 2-3 months median survival extension
Solution Approach 1:
The patent changes the therapeutic parameter from targeting glutamate-mediated excitotoxicity to targeting protein aggregation pathways. This fundamental parameter change involves using compounds that inhibit protein aggregation and modulate proteasome activity, representing a shift in the mechanism of action to address the underlying pathology more effectively
Solution Approach 2:
The patent introduces pyrimidine-2,4,6-trione compounds as intermediary substances that mediate the therapeutic effect by preventing protein aggregation and enhancing proteasome function. These compounds act as mediators between the administered drug and the pathological protein aggregates, facilitating the clearance of toxic aggregates through proteasome activation
2Reliability
If new compounds targeting protein aggregation are developed, then treatment mechanism is improved, but drug development complexity increases
Solution Approach 1:
The pyrimidine-2,4,6-trione compounds exhibit multi-functionality by simultaneously performing multiple therapeutic actions: preventing protein aggregation, modulating proteasome activity, and potentially addressing multiple pathological mechanisms. This universal approach allows a single compound class to tackle various aspects of ALS pathology, reducing the need for multiple separate drug development programs
Data Source
AI summary
The present invention relates to the identification of inventive pyrimidine-2,4,6-triones (PYT compounds) and pharmaceutical compositions thereof for treating subjects with amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. The invention also provides methods of preparing the inventive PYT compounds.